BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

868 related articles for article (PubMed ID: 19770371)

  • 21. Survival in advanced diffuse large B-cell lymphoma in pre- and post-rituximab Eras in the United States.
    Shah BK; Bista A; Shafii B
    Anticancer Res; 2014 Sep; 34(9):5117-20. PubMed ID: 25202101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum BAFF predicts prognosis better than APRIL in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP chemotherapy.
    Kim SJ; Lee SJ; Choi IY; Park Y; Choi CW; Kim IS; Yu W; Hwang HS; Kim BS
    Eur J Haematol; 2008 Sep; 81(3):177-84. PubMed ID: 18510703
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Primary testicular diffuse large B-cell lymphoma shows an activated B-cell-like phenotype.
    Li D; Xie P; Mi C
    Pathol Res Pract; 2010 Sep; 206(9):611-5. PubMed ID: 20627604
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey.
    Tarella C; Zanni M; Magni M; Benedetti F; Patti C; Barbui T; Pileri A; Boccadoro M; Ciceri F; Gallamini A; Cortelazzo S; Majolino I; Mirto S; Corradini P; Passera R; Pizzolo G; Gianni AM; Rambaldi A
    J Clin Oncol; 2008 Jul; 26(19):3166-75. PubMed ID: 18490650
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma.
    Hershman DL; McBride RB; Eisenberger A; Tsai WY; Grann VR; Jacobson JS
    J Clin Oncol; 2008 Jul; 26(19):3159-65. PubMed ID: 18591554
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent advances in the understanding and management of diffuse large B-cell lymphoma in children.
    Reiter A; Klapper W
    Br J Haematol; 2008 Jul; 142(3):329-47. PubMed ID: 18537979
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis.
    Ghesquières H; Berger F; Felman P; Callet-Bauchu E; Bryon PA; Traverse-Glehen A; Thieblemont C; Baseggio L; Michallet AS; Coiffier B; Salles G
    J Clin Oncol; 2006 Nov; 24(33):5234-41. PubMed ID: 17043351
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diffuse large B-cell lymphoma in the young in Japan: a study by the Osaka Lymphoma Study Group.
    Yamauchi A; Fujita S; Ikeda J; Nakamichi I; Fukuhara S; Hino M; Kanakura Y; Ogawa H; Sugiyama H; Kanamaru A; Aozasa K
    Am J Hematol; 2007 Oct; 82(10):893-7. PubMed ID: 17573693
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab.
    Oki Y; Yamamoto K; Kato H; Kuwatsuka Y; Taji H; Kagami Y; Morishima Y
    Eur J Haematol; 2008 Dec; 81(6):448-53. PubMed ID: 18691256
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma.
    Porrata LF; Ristow K; Habermann TM; Witzig TE; Inwards DJ; Markovic SN
    Am J Hematol; 2009 Feb; 84(2):93-7. PubMed ID: 19123458
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ophthalmic lymphoma: epidemiology and pathogenesis.
    Sjö LD
    Acta Ophthalmol; 2009 Feb; 87 Thesis 1():1-20. PubMed ID: 19178392
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States.
    Shenoy PJ; Malik N; Nooka A; Sinha R; Ward KC; Brawley OW; Lipscomb J; Flowers CR
    Cancer; 2011 Jun; 117(11):2530-40. PubMed ID: 24048801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma.
    Griffiths RI; Gleeson ML; Mikhael J; Dreyling MH; Danese MD
    Cancer; 2012 Dec; 118(24):6079-88. PubMed ID: 22648454
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Efficacy of conservative treatment of gastric lymphosarcoma].
    Zvonkov EE; Kremenetskaia AM; Kravchenko SK; Makhinia VA; Kaplanskaia IB; Obukhova TN; Samoĭlova RS; Shevelev AA; Magomedova AU; Bariakh EA; Krasil'nikova BB; Gubkin AV; Iliushkina EA; Mar'in DS; Morozova AK; Kulikov SM; Gemdzhian EG; Vorob'ev AI
    Ter Arkh; 2008; 80(7):18-26. PubMed ID: 18763589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas.
    Zinzani PL; Quaglino P; Pimpinelli N; Berti E; Baliva G; Rupoli S; Martelli M; Alaibac M; Borroni G; Chimenti S; Alterini R; Alinari L; Fierro MT; Cappello N; Pileri A; Soligo D; Paulli M; Pileri S; Santucci M; Bernengo MG;
    J Clin Oncol; 2006 Mar; 24(9):1376-82. PubMed ID: 16492713
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ocular adnexal diffuse large B-cell lymphoma: a multicenter international study.
    Munch-Petersen HD; Rasmussen PK; Coupland SE; Esmaeli B; Finger PT; Graue GF; Grossniklaus HE; Honavar SG; Khong JJ; McKelvie PA; Mulay K; Prause JU; Ralfkiaer E; Sjö LD; Sniegowski MC; Vemuganti GK; Heegaard S
    JAMA Ophthalmol; 2015 Feb; 133(2):165-73. PubMed ID: 25393033
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MGMT methylation in diffuse large B-cell lymphoma: validation of quantitative methylation-specific PCR and comparison with MGMT protein expression.
    Uccella S; Cerutti R; Placidi C; Marchet S; Carnevali I; Bernasconi B; Proserpio I; Pinotti G; Tibiletti MG; Furlan D; Capella C
    J Clin Pathol; 2009 Aug; 62(8):715-23. PubMed ID: 19638543
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diffuse large B-cell lymphoma involving the breast. A report of four cases.
    Pisani F; Romano A; Anticoli Borza P; Marino M; Micheli A; Botti C; Petti MC
    J Exp Clin Cancer Res; 2006 Jun; 25(2):277-81. PubMed ID: 16918141
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma.
    Al-Mansour M; Connors JM; Gascoyne RD; Skinnider B; Savage KJ
    J Clin Oncol; 2010 Feb; 28(5):793-9. PubMed ID: 20048177
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.
    Nyman H; Jerkeman M; Karjalainen-Lindsberg ML; Banham AH; Enblad G; Leppä S
    Eur J Haematol; 2009 May; 82(5):364-72. PubMed ID: 19141121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.